Patents Assigned to Legacy Emanuel Hospital & Health Center
-
Publication number: 20190038627Abstract: Adenosine kinase inhibitors, including pharmaceutical compositions containing the adenosine kinase inhibitors, and their use for preventing epilepsy and its progression in patients. The adenosine kinase inhibitors have the formula: where the moieties J and K, considered in combination, are —CH2—, or K and L, considered in combination, are —CH2—. The R1 moiety can be —NH2, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 hydroxyalkyl. The R2 and R3 moieties are each independently C1-C6 alkyl. The R4 moiety is hydrogen or C1-C6 alkyl. The R5 and R6 moieties are each independently C6-C12 aryl, C3-C8 cycloalkyl, or C3-C8 heteroaryl, that is optionally further substituted.Type: ApplicationFiled: July 9, 2018Publication date: February 7, 2019Applicants: Legacy Emanuel Hospital & Health Center, The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Kenneth Alan Jacobson, Detlev Boison, Kiran Shambhu Toti
-
Patent number: 10016432Abstract: Adenosine kinase inhibitors, including pharmaceutical compositions containing the adenosine kinase inhibitors, and their use for preventing epilepsy and its progression in patients. The adenosine kinase inhibitors have the formula: where the moieties J and K, considered in combination, are —CH2—, or K and L, considered in combination, are —CH2—. The R1 moiety can be —NH2, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 hydroxyalkyl. The R2 and R3 moieties are each independently C1-C6 alkyl. The R4 moiety is hydrogen or C1-C6 alkyl. The R5 and R6 moieties are each independently C6-C12 aryl, C3-C8 cycloalkyl, or C3-C8 heteroaryl, that is optionally further substituted.Type: GrantFiled: May 26, 2017Date of Patent: July 10, 2018Assignees: Legacy Emanuel Hospital & Health Center, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Kenneth Alan Jacobson, Detlev Boison, Kiran Shambhu Toti
-
Publication number: 20170340640Abstract: Adenosine kinase inhibitors, including pharmaceutical compositions containing the adenosine kinase inhibitors, and their use for preventing epilepsy and its progression in patients. The adenosine kinase inhibitors have the formula: where the moieties J and K, considered in combination, are —CH2—, or K and L, considered in combination, are —CH2—. The R1 moiety can be —NH2, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 hydroxyalkyl. The R2 and R3 moieties are each independently C1-C6 alkyl. The R4 moiety is hydrogen or C1-C6 alkyl. The R5 and R6 moieties are each independently C6-C12 aryl, C3-C8 cycloalkyl, or C3-C8 heteroaryl, that is optionally further substituted.Type: ApplicationFiled: May 26, 2017Publication date: November 30, 2017Applicants: Legacy Emanuel Hospital & Health Center, The United States of America, as represented by The Secretary, Department of Health and Human ServInventors: Kenneth Alan Jacobson, Detlev Boison, Kiran Shambhu Toti
-
Publication number: 20170219562Abstract: Epigenetic compound screening platform, including methods and cell lines. In an exemplary screening method, ADK-null, ADK-L, and ADK-S cell lines may be selected. The ADK-null cell line may express no ADK protein. The ADK-L cell line may express only the long (L), nuclear isoform of a mammalian ADK protein from an exogenous construct. The ADK-S cell line may express only the short (S), cytoplasmic isoform of a mammalian ADK protein from an exogenous construct. Each of the cell lines may be exposed to the same test compound. A level of DNA or histone methylation, or DNA or histone methyltransferase activity for each of the exposed cell lines may be measured. The level for each exposed cell line may be compared to a corresponding level measured without exposure to the test compound, to determine whether the test compound affects DNA or histone methylation, or DNA or histone methyltransferase activity, in any of the cell lines.Type: ApplicationFiled: January 27, 2017Publication date: August 3, 2017Applicant: Legacy Emanuel Hospital & Health CenterInventors: Detlev Boison, Ursula Susan Sandau
-
Publication number: 20170095497Abstract: Methods of anti-epileptogenesis treatment in which adenosine kinase (ADK) activity or expression is inhibited only transiently to provide a long-term benefit to a non-epileptic or epileptic subject. In an exemplary method, a therapeutically effective amount of an ADK inhibitor may be administered to a human non-epileptic subject over a finite, predetermined treatment period having a duration of less than two months. The non-epileptic subject may have sustained a precipitating event with a known risk to trigger latent development of an acquired form of epilepsy. Administration of the ADK inhibitor to the subject may be stopped at the end of the treatment period for at least the longer of (i) six months and (ii) ten times the duration of the treatment period. The step of administering may reduce the chance of the subject having seizures caused by the acquired form of epilepsy for an extended period following the end of the treatment period.Type: ApplicationFiled: October 3, 2016Publication date: April 6, 2017Applicant: Legacy Emanuel Hospital & Health CenterInventors: Detlev Boison, Ursula Susan Sandau
-
Patent number: 8636711Abstract: Stabilized glucagon solutions, methods of storing and using the stabilized glucagon solutions, and drug delivery devices containing the stabilized glucagon solutions. In some embodiments, the glucagon solutions may be alkaline, such as with a pH of at least about 9. The glucagon solutions may be resistant to aggregation of glucagon when the solutions are stored for a prolonged period, such as at least about three days, at room temperature and/or physiological temperature.Type: GrantFiled: June 14, 2011Date of Patent: January 28, 2014Assignees: Legacy Emanuel Hospital & Health Center, Indian University Research and Technology CorporationInventors: W. Kenneth Ward, Richard D. DiMarchi
-
Patent number: 8609366Abstract: Systems and methods for providing dynamic mechanical loading and mechanical property assessment of tissue cultures in open dish cultures are provided. An actuator may be provided under a cell culture dish for driving the dish upward toward a fixed post member, thereby providing controlled compression of a tissue sample.Type: GrantFiled: November 7, 2006Date of Patent: December 17, 2013Assignee: Legacy Emanuel Hospital & Health CenterInventors: Michael Bottlang, Mark B. Sommers
-
Patent number: 8304202Abstract: Methods, compositions, and cells for drug screening based on interaction between a Bim polypeptide and a TRIM2 polypeptide. Methods and compositions for treating cancer based on tested levels of Bim and TRIM2 proteins are also provided.Type: GrantFiled: January 29, 2010Date of Patent: November 6, 2012Assignee: Legacy Emanuel Hospital & Health CenterInventor: Robert Meller
-
Publication number: 20120071817Abstract: Stabilized glucagon solutions, methods of storing and using the stabilized glucagon solutions, and drug delivery devices containing the stabilized glucagon solutions. In some embodiments, the glucagon solutions may be alkaline, such as with a pH of at least about 9. The glucagon solutions may be resistant to aggregation of glucagon when the solutions are stored for a prolonged period, such as at least about three days, at room temperature and/or physiological temperature.Type: ApplicationFiled: June 14, 2011Publication date: March 22, 2012Applicant: Legacy Emanuel Hospital & Health CenterInventors: W. Kenneth Ward, Richard D. DiMarchi
-
Patent number: 8114023Abstract: Electrochemical systems for measuring an analyte concentration, and correcting any surplus or deficiency in the measured concentration. More specifically, systems for measuring an analyte level in a fluid with an implantable sensor, processing the measurements with an algorithm, and determining an appropriate fluid infusion rate in response to the measurements.Type: GrantFiled: November 1, 2006Date of Patent: February 14, 2012Assignee: Legacy Emanuel Hospital & Health CenterInventors: W. Kenneth Ward, Michael D. Wood, Heather M. Duman, Bala Nair
-
Patent number: 7892764Abstract: Systems, including methods and compositions, for seizure suppression, such as inhibition of epileptic seizures. In some embodiments, the methods may provide a screen for anti-seizure drugs. One or more compositions may be selected based on an ability to affect a response of biological cells to a change in extracellular pH and/or to affect an activity of at least one acid sensing ion channel (ASIC). Based on the one or more compositions selected, at least one drug candidate may be assayed for inhibition of seizure-like electrical activity and/or seizures. In some embodiments, the methods and compositions may, respectively, administer and provide an effective amount of PcTX1, a peptide derivative of PcTX1 amiloride, an amiloride derivative, or a combination thereof to a subject prone to seizures and/or having a seizure, in order to suppress seizure activity.Type: GrantFiled: November 21, 2007Date of Patent: February 22, 2011Assignee: Legacy Emanuel Hospital & Health CenterInventors: Zhigang Xiong, Roger P. Simon
-
Publication number: 20100203552Abstract: Methods, compositions, and cells for drug screening based on interaction between a Bim polypeptide and a TRIM2 polypeptide. Methods and compositions for treating cancer based on tested levels of Bim and TRIM2 proteins are also provided.Type: ApplicationFiled: January 29, 2010Publication date: August 12, 2010Applicant: Legacy Emanuel Hospital & Health CenterInventor: Robert Meller
-
Publication number: 20090029925Abstract: Methods, compositions, and cells for drug screening based on interaction between (1) a Bim polypeptide and/or an E2 polypeptide and (2) a TRIM2 polypeptide, which is identical to or corresponds to a Bim-selective E3 ubiquitin ligase. Methods and compositions for treating cancer based on levels of Bim protein, TRIM2 protein, and active MAPK protein are also provided.Type: ApplicationFiled: July 23, 2008Publication date: January 29, 2009Applicant: LEGACY EMANUEL HOSPITAL & HEALTH CENTERInventor: Robert Meller
-
Publication number: 20080242588Abstract: Systems, including methods and compositions, for seizure suppression, such as inhibition of epileptic seizures. In some embodiments, the methods may provide a screen for anti-seizure drugs. One or more compositions may be selected based on an ability to affect a response of biological cells to a change in extracellular pH and/or to affect an activity of at least one acid sensing ion channel (ASIC). Based on the one or more compositions selected, at least one drug candidate may be assayed for inhibition of seizure-like electrical activity and/or seizures. In some embodiments, the methods and compositions may, respectively, administer and provide an effective amount of PcTX1, a peptide derivative of PcTX1 amiloride, an amiloride derivative, or a combination thereof to a subject prone to seizures and/or having a seizure, in order to suppress seizure activity.Type: ApplicationFiled: November 21, 2007Publication date: October 2, 2008Applicant: Legacy Emanuel Hospital & Health CenterInventors: Zhigang Xiong, Roger P. Simon